院外心脏骤停给药途径的随机试验
这项在英国11个急救医疗服务系统开展的多中心、开放标签、随机试验,纳入需要血管通路给药的院外心脏骤停成人,随机分为骨内优先或静脉优先血管通路策略,由护理人员实施。主要终点30天生存率:骨内组4.5%(137/3030)vs 静脉组5.1%(155/3034),校正OR 0.94(95%CI 0.68-1.32,P=0.74)。出院时良好神经功能(改良Rankin量表≤3分)骨内组2.7%(80/2994)vs 静脉组2.8%(85/2986),校正OR 0.91(95%CI 0.57-1.47);任何时间自主循环恢复骨内组36.0%(1092/3031)vs 静脉组39.1%(1186/3035),校正OR 0.86(95%CI 0.76-0.97)。试验期间报告1例不良事件,发生在骨内组。
要点
- 院外心脏骤停成人需要血管通路给药时,骨内优先策略30天生存率4.5%(137/3030)vs 静脉优先5.1%(155/3034),校正OR 0.94(95%CI 0.68-1.32,P=0.74)。
- 出院时良好神经功能(改良Rankin量表≤3分)骨内组2.7%(80/2994)vs 静脉组2.8%(85/2986),校正OR 0.91(95%CI 0.57-1.47)。
- 任何时间自主循环恢复骨内组36.0%(1092/3031)vs 静脉组39.1%(1186/3035),校正OR 0.86(95%CI 0.76-0.97)。
- 试验期间报告1例不良事件,发生在骨内组。
- 主要终点未校正多重比较。
适用人群与场景
- 英国11个急救医疗服务系统内的院外心脏骤停成人,需要血管通路给予药物。
处置流程与药物剂量
- 由护理人员按随机分配实施骨内优先或静脉优先血管通路策略给药。
研究设计与关键结果
- 多中心、开放标签、随机试验,纳入6082例患者,骨内组3040例、静脉组3042例。
- 30天生存:骨内组4.5%(137/3030)vs 静脉组5.1%(155/3034),校正OR 0.94(95%CI 0.68-1.32,P=0.74)。
- 出院时良好神经功能(改良Rankin量表≤3分):骨内组2.7%(80/2994)vs 静脉组2.8%(85/2986),校正OR 0.91(95%CI 0.57-1.47)。
- 任何时间自主循环恢复:骨内组36.0%(1092/3031)vs 静脉组39.1%(1186/3035),校正OR 0.86(95%CI 0.76-0.97)。
- 试验期间报告1例不良事件,发生在骨内组。
- 主要终点未校正多重比较。
证据类型、等级与局限
- 多中心、开放标签、随机试验(PARAMEDIC-3),由英国国家卫生与护理研究所资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 院外心脏骤停成人需要药物治疗时,骨内优先血管通路策略未较静脉优先策略提高30天生存率(4.5% vs 5.1%,校正OR 0.94,95%CI 0.68-1.32,P=0.74)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with out-of-hospital cardiac arrest, the effectiveness of drugs such as epinephrine is highly time-dependent. An intraosseous route of drug administration may enable more rapid drug administration than an intravenous route; however, its effect on clinical outcomes is uncertain.
METHODS: We conducted a multicenter, open-label, randomized trial across 11 emergency medical systems in the United Kingdom that involved adults in cardiac arrest for whom vascular access for drug administration was needed. Patients were randomly assigned to receive treatment from paramedics by means of an intraosseous-first or intravenous-first vascular access strategy. The primary outcome was survival at 30 days. Key secondary outcomes included any return of spontaneous circulation and favorable neurologic function at hospital discharge (defined by a score of 3 or less on the modified Rankin scale, on which scores range from 0 to 6, with higher scores indicating greater disability). No adjustment for multiplicity was made.
RESULTS: A total of 6082 patients were assigned to a trial group: 3040 to the intraosseous group and 3042 to the intravenous group. At 30 days, 137 of 3030 patients (4.5%) in the intraosseous group and 155 of 3034 (5.1%) in the intravenous group were alive (adjusted odds ratio, 0.94; 95% confidence interval [CI], 0.68 to 1.32; P = 0.74). At the time of hospital discharge, a favorable neurologic outcome was observed in 80 of 2994 patients (2.7%) in the intraosseous group and in 85 of 2986 (2.8%) in the intravenous group (adjusted odds ratio, 0.91; 95% CI, 0.57 to 1.47); a return of spontaneous circulation at any time occurred in 1092 of 3031 patients (36.0%) and in 1186 of 3035 patients (39.1%), respectively (adjusted odds ratio, 0.86; 95% CI, 0.76 to 0.97). During the trial, one adverse event, which occurred in the intraosseous group, was reported.
CONCLUSIONS: Among adults with out-of-hospital cardiac arrest requiring drug therapy, the use of an intraosseous-first vascular access strategy did not result in higher 30-day survival than an intravenous-first strategy. (Funded by the National Institute for Health and Care Research; PARAMEDIC-3 ISRCTN Registry number, ISRCTN14223494.).
参考来源
- Couper K, Ji C, Deakin CD, et al. A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2024. PMID: 39480216. doi:10.1056/NEJMoa2407780
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。